RNS & Investor News

2024

Result of AGM

09 July 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high

cholesterol, diabetes and skincare, announces that at the Annual General Meeting (ÒAGMÓ) held earlier today, all resolutions were duly passed.

As shareholders were unable to attend the AGM in person as a result of the ongoing pandemic, they were given the option to submit questions in advance. These questions have been addressed and will be available to view on the website, along with the voting results, later today: https://www.optibiotix-ir.com/content/investors/shareholder-information

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome Ð the collective genome of the microbes in the body Ð in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The CompanyÕs current areas of focus include obesity, cardiovascular health, and diabetes. 

2023

Result of AGM

09 July 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high

cholesterol, diabetes and skincare, announces that at the Annual General Meeting (ÒAGMÓ) held earlier today, all resolutions were duly passed.

As shareholders were unable to attend the AGM in person as a result of the ongoing pandemic, they were given the option to submit questions in advance. These questions have been addressed and will be available to view on the website, along with the voting results, later today: https://www.optibiotix-ir.com/content/investors/shareholder-information

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome Ð the collective genome of the microbes in the body Ð in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The CompanyÕs current areas of focus include obesity, cardiovascular health, and diabetes. 

2022

Result of AGM

09 July 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high

cholesterol, diabetes and skincare, announces that at the Annual General Meeting (ÒAGMÓ) held earlier today, all resolutions were duly passed.

As shareholders were unable to attend the AGM in person as a result of the ongoing pandemic, they were given the option to submit questions in advance. These questions have been addressed and will be available to view on the website, along with the voting results, later today: https://www.optibiotix-ir.com/content/investors/shareholder-information

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome Ð the collective genome of the microbes in the body Ð in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The CompanyÕs current areas of focus include obesity, cardiovascular health, and diabetes. 

2021

Result of AGM

09 July 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high

cholesterol, diabetes and skincare, announces that at the Annual General Meeting (ÒAGMÓ) held earlier today, all resolutions were duly passed.

As shareholders were unable to attend the AGM in person as a result of the ongoing pandemic, they were given the option to submit questions in advance. These questions have been addressed and will be available to view on the website, along with the voting results, later today: https://www.optibiotix-ir.com/content/investors/shareholder-information

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome Ð the collective genome of the microbes in the body Ð in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The CompanyÕs current areas of focus include obesity, cardiovascular health, and diabetes. 

2020

Result of AGM

09 July 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high

cholesterol, diabetes and skincare, announces that at the Annual General Meeting (ÒAGMÓ) held earlier today, all resolutions were duly passed.

As shareholders were unable to attend the AGM in person as a result of the ongoing pandemic, they were given the option to submit questions in advance. These questions have been addressed and will be available to view on the website, along with the voting results, later today: https://www.optibiotix-ir.com/content/investors/shareholder-information

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome Ð the collective genome of the microbes in the body Ð in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The CompanyÕs current areas of focus include obesity, cardiovascular health, and diabetes. 

2019

Result of AGM

09 July 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high

cholesterol, diabetes and skincare, announces that at the Annual General Meeting (ÒAGMÓ) held earlier today, all resolutions were duly passed.

As shareholders were unable to attend the AGM in person as a result of the ongoing pandemic, they were given the option to submit questions in advance. These questions have been addressed and will be available to view on the website, along with the voting results, later today: https://www.optibiotix-ir.com/content/investors/shareholder-information

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome Ð the collective genome of the microbes in the body Ð in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The CompanyÕs current areas of focus include obesity, cardiovascular health, and diabetes. 

2018

Result of AGM

09 July 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high

cholesterol, diabetes and skincare, announces that at the Annual General Meeting (ÒAGMÓ) held earlier today, all resolutions were duly passed.

As shareholders were unable to attend the AGM in person as a result of the ongoing pandemic, they were given the option to submit questions in advance. These questions have been addressed and will be available to view on the website, along with the voting results, later today: https://www.optibiotix-ir.com/content/investors/shareholder-information

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome Ð the collective genome of the microbes in the body Ð in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The CompanyÕs current areas of focus include obesity, cardiovascular health, and diabetes. 

2017

Result of AGM

09 July 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high

cholesterol, diabetes and skincare, announces that at the Annual General Meeting (ÒAGMÓ) held earlier today, all resolutions were duly passed.

As shareholders were unable to attend the AGM in person as a result of the ongoing pandemic, they were given the option to submit questions in advance. These questions have been addressed and will be available to view on the website, along with the voting results, later today: https://www.optibiotix-ir.com/content/investors/shareholder-information

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome Ð the collective genome of the microbes in the body Ð in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The CompanyÕs current areas of focus include obesity, cardiovascular health, and diabetes. 

2016

Result of AGM

09 July 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high

cholesterol, diabetes and skincare, announces that at the Annual General Meeting (ÒAGMÓ) held earlier today, all resolutions were duly passed.

As shareholders were unable to attend the AGM in person as a result of the ongoing pandemic, they were given the option to submit questions in advance. These questions have been addressed and will be available to view on the website, along with the voting results, later today: https://www.optibiotix-ir.com/content/investors/shareholder-information

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome Ð the collective genome of the microbes in the body Ð in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The CompanyÕs current areas of focus include obesity, cardiovascular health, and diabetes. 

2015

Result of AGM

09 July 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high

cholesterol, diabetes and skincare, announces that at the Annual General Meeting (ÒAGMÓ) held earlier today, all resolutions were duly passed.

As shareholders were unable to attend the AGM in person as a result of the ongoing pandemic, they were given the option to submit questions in advance. These questions have been addressed and will be available to view on the website, along with the voting results, later today: https://www.optibiotix-ir.com/content/investors/shareholder-information

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome Ð the collective genome of the microbes in the body Ð in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The CompanyÕs current areas of focus include obesity, cardiovascular health, and diabetes. 

2014

Result of AGM

09 July 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high

cholesterol, diabetes and skincare, announces that at the Annual General Meeting (ÒAGMÓ) held earlier today, all resolutions were duly passed.

As shareholders were unable to attend the AGM in person as a result of the ongoing pandemic, they were given the option to submit questions in advance. These questions have been addressed and will be available to view on the website, along with the voting results, later today: https://www.optibiotix-ir.com/content/investors/shareholder-information

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome Ð the collective genome of the microbes in the body Ð in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The CompanyÕs current areas of focus include obesity, cardiovascular health, and diabetes. 

2013

Result of AGM

09 July 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high

cholesterol, diabetes and skincare, announces that at the Annual General Meeting (ÒAGMÓ) held earlier today, all resolutions were duly passed.

As shareholders were unable to attend the AGM in person as a result of the ongoing pandemic, they were given the option to submit questions in advance. These questions have been addressed and will be available to view on the website, along with the voting results, later today: https://www.optibiotix-ir.com/content/investors/shareholder-information

 

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome Ð the collective genome of the microbes in the body Ð in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The CompanyÕs current areas of focus include obesity, cardiovascular health, and diabetes.